Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays. Granulocyte colony-stimulating factors (G-CSFs) stimulate neutrophil production and may reduce FN incidence when given prophylactically following chemotherapy.
Methods
A systematic review and meta-analysis assessed the effectiveness of G-CSFs (pegfilgrastim, filgrastim or lenograstim) in reducing FN incidence in adults undergoing chemotherapy for solid tumours or lymphoma. G-CSFs were compared with no primary G-CSF prophylaxis and with one another. Nine databases were searched in December 2009. Meta-analysis used a random effects model due to heterogeneity.
Results
Twenty studies compared primary G-CSF prophylaxis with no primary G-CSF prophylaxis: five studies of pegfilgrastim; ten of filgrastim; and five of lenograstim. All three G-CSFs significantly reduced FN incidence, with relative risks of 0.30 (95% CI: 0.14 to 0.65) for pegfilgrastim, 0.57 (95% CI: 0.48 to 0.69) for filgrastim, and 0.62 (95% CI: 0.44 to 0.88) for lenograstim. Overall, the relative risk of FN for any primary G-CSF prophylaxis versus no primary G-CSF prophylaxis was 0.51 (95% CI: 0.41 to 0.62). In terms of comparisons between different G-CSFs, five studies compared pegfilgrastim with filgrastim. FN incidence was significantly lower for pegfilgrastim than filgrastim, with a relative risk of 0.66 (95% CI: 0.44 to 0.98).
Conclusions
Primary prophylaxis with G-CSFs significantly reduces FN incidence in adults undergoing chemotherapy for solid tumours or lymphoma. Pegfilgrastim reduces FN incidence to a significantly greater extent than filgrastim.
The online version of this article (doi:10.1186/1471-2407-11-404) contains supplementary material, which is available to authorized users.
Competing interests
The research underlying this paper was funded by Amgen Ltd, and a research grant from Amgen (EUROPE) GmbH was provided to support the production of the manuscript. Amgen staff reviewed and made suggested edits to the manuscript, but final content, authorship and right to publication remained with the research team.
Authors' contributions
KC undertook the systematic review and drafted the manuscript. JM undertook the statistical analyses. SW contributed to study selection and interpretation. MS contributed to study selection and interpretation and to the statistical analyses. RA participated in the design and coordination of the study and contributed to the statistical analyses. All authors read and approved the final manuscript.
Abkürzungen
ANC
Absolute neutrophil count
ASCO
American Society of Clinical Oncology
DARE
Database of Abstracts of Reviews of Effects
EORTC
European Organisation for Research and Treatment of Cancer
FN
Febrile neutropenia
G-CSF
Granulocyte colony-stimulating factor
NCCN
National Comprehensive Cancer Network
NHS-EED
NHS Economic Evaluation Database
RCT
Randomised controlled trial.
Background
Neutropenia is the major dose-limiting toxicity of many chemotherapy regimens. Grade 3 and grade 4 neutropenia are defined as a neutrophil count < 1.0 × 109/L and < 0.5 × 109/L respectively. Febrile neutropenia (FN) is defined as neutropenia with fever, usually indicating infection, and is associated with substantial morbidity, mortality, and costs [1]. The direct risk of mortality associated with FN has been estimated as 9.5% (95% confidence interval [CI]: 9.2%, 9.8%) in a study of 41,779 cancer patients hospitalised with FN [1]. Management of FN often requires lengthy hospitalisation, [1] with associated costs and detrimental effects on quality of life [2, 3]. In addition, an FN episode has been shown to increase the risk of chemotherapy dose reductions and delays [4]. Unplanned reductions in chemotherapy dose may cause further deaths from cancer in the long-term; in a retrospective analysis of breast cancer patients with a 30-year follow-up, the survival rate was 40% (95% CI: 26%, 55%) among patients receiving at least 85% of their planned dose, but only 21% (95% CI: 14%, 26%) among patients who received less than 85% [5].
Recombinant human granulocyte colony-stimulating factors (G-CSFs) stimulate production of mature, functional neutrophils [6]. G-CSFs have been shown to reduce the incidence of FN when used as prophylaxis following chemotherapy. Three G-CSFs are currently in common usage: filgrastim, pegfilgrastim, and lenograstim. Filgrastim and lenograstim are administered as a series of daily injections; clinical studies suggest an average of 11 injections per chemotherapy cycle are required to achieve recovery of the absolute neutrophil count (ANC) to within the normal range [7‐10]. Pegfilgrastim is administered as a single injection per chemotherapy cycle [11, 12]. G-CSFs may be administered as primary prophylaxis (in every chemotherapy cycle from cycle 1) or as secondary prophylaxis (in all remaining cycles following a neutropenic event such as FN or prolonged severe neutropenia). The overall FN risk is dependent on chemotherapy regimen as well as individual patient risk factors such as age, performance status and disease stage [13]. Guidelines from the European Organisation for Research and Treatment of Cancer (EORTC), [13] the American Society of Clinical Oncology (ASCO) [14] and the National Comprehensive Cancer Network (NCCN) [15] recommend that prophylactic G-CSFs should be used where the risk of FN associated with the chemotherapy regimen is greater than or equal to 20%, and may be considered where the risk is 10-20%, particularly where additional patient risk factors are present.
Anzeige
This paper reports a systematic review and meta-analysis of the effect of primary G-CSF prophylaxis (with pegfilgrastim, filgrastim or lenograstim) on incidence of FN. The effect of each G-CSF is assessed in comparison with no primary G-CSF prophylaxis and in comparison with other G-CSFs.
Methods
Search strategy
The systematic review followed the recommendations in the PRISMA statement [16, 17]. A systematic search was undertaken to identify randomised controlled trials (RCTs) of pegfilgrastim, filgrastim or lenograstim, compared with no primary G-CSF or with one another, for the reduction of FN following chemotherapy. A previous systematic review by Kuderer et al. [18] presented a meta-analysis of FN incidence within RCTs of primary G-CSF prophylaxis versus no primary G-CSF prophylaxis, while a systematic review by Pinto et al. [19] meta-analysed RCTs of primary prophylaxis using pegfilgrastim versus filgrastim. The literature searches within these previous reviews were conducted during 2006. Therefore, databases were searched from 2006 onwards, whereas studies published prior to 2006 were identified from the two existing reviews. Searches were undertaken in December 2009. The following databases were searched: Medline, Medline in Process, EMBASE, Science Citation Index, Cochrane Database of Systematic Reviews, Cochrane CENTRAL Register of Controlled Trials, Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database and NHS Economic Evaluation Database (NHS-EED). The Medline search strategy was designed with reference to the previous two reviews, and comprised subject headings and text words for G-CSFs combined with a search filter to identify RCTs (Appendix 1). Searches were not restricted by language. Bibliographies of retrieved papers were searched for any additional relevant studies.
Inclusion and exclusion criteria
Studies were considered suitable for inclusion if they assessed primary G-CSF prophylaxis (pegfilgrastim, filgrastim or lenograstim) administered 1-3 days after the completion of chemotherapy, versus a different G-CSF or versus no primary G-CSF prophylaxis. Studies were only included if they reported incidence of FN. For consistency with the two existing systematic reviews, [18, 19] only studies of adult cancer patients with solid tumours or lymphoma were included. Studies allowing concomitant antibiotic prophylaxis were included if identical prophylaxis was administered in both study arms. The following study types were excluded: studies of G-CSFs for treatment of FN; studies in children; studies in patients with leukaemia, myeloid malignancies or myelodysplastic syndromes; studies of G-CSFs for stem cell mobilisation in bone marrow or peripheral blood stem cell transplantation; economic analyses; studies with differing drugs, doses or schedules of chemotherapy in each arm; studies with differing doses of the same G-CSF in each arm; and studies not published in English.
Outcome measures
The outcome measure assessed in this review was the incidence of FN over all cycles of chemotherapy within each study. FN was chosen as a key clinical outcome due to its direct bearing on morbidity, mortality and hospitalisation rates, and also because this review was undertaken alongside the development of an economic model which utilised FN rate as a key parameter.
Anzeige
Data extraction
Data was extracted by two reviewers using a form developed for this review and any discrepancies were resolved through discussion.
Data synthesis
Meta-analyses were undertaken to compare the effectiveness of G-CSFs versus no prophylaxis and versus each other for the reduction of FN. Analyses were undertaken using RevMan software (version 5, Cochrane Collaboration). Results for each comparison were presented as a pooled relative risk and 95% CIs. Although clinical and statistical heterogeneity existed between studies, there was insufficient data on individual populations to facilitate separate analyses. Therefore, for consistency with existing reviews, all studies were included in the analysis, and a random effects model was used. Heterogeneity was presented using the I2 statistic, which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) [20].
Results
Number and characteristics of included studies
The flow chart for study inclusion is shown in Figure 1 and the included studies are described in Table 1. Studies published from 2006 onwards were identified from the literature search, and studies published prior to 2006 were identified from two previous reviews [18, 19]. In total, 23 citations relating to 25 studies satisfied the inclusion criteria: 5 studies of primary pegfilgrastim vs. no primary G-CSF (within 4 citations); [21‐24] 10 studies of primary filgrastim vs. no primary G-CSF (within 9 citations); [25‐33] 5 studies of primary lenograstim vs. no primary G-CSF; [9, 10, 34‐36] and 5 studies of primary pegfilgrastim vs. primary filgrastim [7, 8, 37‐39]. No studies were identified comparing lenograstim with either pegfilgrastim alone or filgrastim alone.
Figure 1
Flow chart for identification of relevant studies.
×
Table 1
Description of trials of primary G-CSFs (vs. no primary G-CSF, or vs. each other)
Filgrastim primary: 5 ug/kg, from day 2 up to 12d or until ANC = 10 × 109/l
31
11 (median)
Fever + ANC < 0.5 × 109/l
a Studies added as a result of updated search. b G-CSF strategy: Primary prophylaxis is in all cycles. Secondary prophylaxis is in all cycles following FN, or following FN or neutropenia, or at physician's discretion (as noted for individual studies). ANC = absolute neutrophil count; DB = double-blind; DF = dose-finding; HL = Hodgkin's lymphoma; NHL = non-Hodgkin's lymphoma; OL = open-label; SCLC = small-cell lung cancer. Chemotherapy regimens used: BEP/EP = etoposide 100 mg/m2, cisplatin 20 mg/m2, plus or minus bleomycin 30 U. BOP/VIP-B = bleomycin 30 U, vincristine 2 mg, cisplatin 20-50 mg/m2/etoposide 100 mg/m2, ifosfamide 1000 mg/m2. CDE = cyclophosphamide 1 g/m2, doxorubicin 45-50 mg/m2, etoposide 100-120 mg/m2. CHOP = cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, prednisolone 100 mg days 1-5. CNOP = cyclophosphamide 750 mg/m2, mitoxantrone 10 mg/m2, vincristine 1.4 mg/m2, prednisolone 50 mg/m2 days 1-5. ESHAP = etoposide 40 mg/m2, methylprednisolone 500 mg, cisplatin 25 mg/m2/d, cytarabine 2000 mg/m2. FEC-100 = 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2. FEC-high-dose = 5-fluorouracil 750 mg/m2, epirubicin 35 mg/m2, cyclophosphamide 400 mg/m2. FOIL = 5-FU, oxaliplatin, irinotecan, leucovorin. FOLFIRI = 5-FU, irinotecan, leucovorin. FOLFOX = 5-FU, oxaliplatin, leucovorin. LNH-87 = cyclophosphamide 1200 mg/m2 day 1, vindesine 2 mg/m2 days 1 & 5, bleomycin 10 mg days 1 & 5, prednisolone 60 mg/m2 days 1-5, methotrexate 15 mg, with either doxorubicin 75 mg/m2 or mitoxantrone 12 mg/m2 day 1. MAID = mesna, doxorubicin, ifosfamide, dacarbazine. R-CHOP = CHOP plus rituximab. TAC = doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2, docetaxel 75 mg/m2. VAPEC-B = vincristine 1.4 mg/m2, doxorubicin 35 mg/m2 prednisolone 50 mg/d (then tapered), etoposide 100 mg/m2, cyclophosphamide 350 mg/m2, bleomycin 10 mg/m2. VNCOP-B = vincristine 2 mg, mitoxantrone 10 mg/m2, cyclophosphamide 300 mg/m2, etoposide 150 mg/m2, prednisone 40 mg, bleomycin 10 mg/m2.
A previous systematic review of prophylactic G-CSF use [18] included only a single study of pegfilgrastim versus no primary G-CSF [21]. Our literature search identified 4 additional RCTs of pegfilgrastim vs. no primary G-CSF, which were conducted in populations with colorectal cancer, [24] breast cancer, [23] non-Hodgkin's lymphoma, [22] and various solid tumours; [22] the latter three studies were restricted to elderly patients. Our review also identified an additional large RCT of filgrastim vs. no primary G-CSF in breast cancer [33].
There was heterogeneity among trials of all three G-CSFs in terms of cancer type, patient age, chemotherapy regimen, number of chemotherapy cycles and cycle length (Table 1). Filgrastim and lenograstim were generally given for 10-14 days where the chemotherapy cycle length was 3 weeks (and for fewer days in a small number of trials with shorter cycle lengths). The comparator arm in some of the studies included secondary G-CSFs for those patients having an FN event, and some trials allowed prophylactic antibiotics in both arms. Some studies were open-label rather than double-blind.
Effectiveness of G-CSFs in reducing febrile neutropenia incidence
The relative risks of FN incidence are shown in Figure 2 for trials of G-CSF versus no primary G-CSF, and in Figure 3 for trials of pegfilgrastim versus filgrastim. The pooled relative risks for each G-CSF comparison are summarised in Table 2. Primary prophylaxis with each of the G-CSFs significantly decreased the risk of FN compared with no primary G-CSF, with relative risks of 0.30 (95% CI: 0.14 to 0.65) for pegfilgrastim, 0.57 (95% CI: 0.48 to 0.69) for filgrastim, and 0.62 (95% CI: 0.44 to 0.88) for lenograstim. Overall, the relative risk of FN when using any primary G-CSF prophylaxis versus no primary G-CSF prophylaxis was 0.51 (95% CI: 0.41 to 0.62).
Figure 2
Primary G-CSFs versus no primary G-CSF: FN incidence. Cancer types for each study are shown after the author and date. CHOP and CNOP = chemotherapy regimens for NHL (see Table 1 footnote); NHL = non-Hodgkin's lymphoma; SCLC = small-cell lung cancer; solid = solid tumours. *Indicates studies in patients aged ≥ 60 or ≥ 65 years.
Figure 3
Pegfilgrastim versus filgrastim: FN incidence. Cancer types for each study are shown after the author and date. HL = Hodgkin's lymphoma; NHL = non-Hodgkin's lymphoma. *Indicates studies in patients aged ≥ 60 or ≥ 65 years. In the Holmes 2002 (phase II) study,[37] FN incidence in the filgrastim arm was reported as 2/25, which was incorrectly converted to 12%. The absolute numbers (2/25) have been used in this analysis. Therefore the resulting relative risk differs slightly from that reported in the previous systematic review by Pinto (2007),[19] which used the 12% figure.
×
×
Table 2
Summary of febrile neutropenia incidence based on meta-analyses of trials of G-CSFs
Treatment 1
Treatment 2
No of studies
No of patients
Relative risk of FN (95% CI)
p-value
I2 (heterogeneity)
Pegfilgrastim
No primary G-CSF
5
2060
0.30 (0.14 to 0.65)
p = 0.002
76%
Filgrastim
No primary G-CSF
10
2183
0.57 (0.48 to 0.69)
p < 0.00001
50%
Lenograstim
No primary G-CSF
5
467
0.62 (0.44 to 0.88)
p = 0.007
64%
Any G-CSF
No primary G-CSF
20
4710
0.51 (0.41 to 0.62)
p < 0.00001
74%
Pegfilgrastim
Filgrastim
5
606
0.66 (0.44 to 0.98)
p = 0.04
0%
There was a relatively high level of statistical heterogeneity in the analyses as shown by the I2 statistic, which ranged from 50-76%; this is likely to reflect the variations between studies in factors such as cancer type, patient age, chemotherapy regimen, number of chemotherapy cycles and cycle length. Individual studies differed on too many variables for formal sub-analyses to be meaningful. However, Figures 2 and 3 illustrate the cancer type for each study (shown after the author and date) and highlight studies in populations aged ≥ 60 or ≥ 65 years (shown by asterisks). There was no clear difference in G-CSF effectiveness between cancer types, nor in studies restricting to an elderly population. As the majority of studies administered filgrastim and lenograstim for 10-14 days (for 3-week chemotherapy cycles), there was insufficient data to assess the effects of shorter durations of G-CSF treatment.
In terms of comparisons between different G-CSFs, the relative risk of FN for pegfilgrastim versus filgrastim was 0.66 (95% CI: 0.44 to 0.98). There were no head-to-head trials comparing lenograstim to either of the other two G-CSFs.
Anzeige
Discussion
Our systematic review and meta-analyses confirm and strengthen previous evidence that primary prophylaxis with each of the three G-CSFs is effective in reducing the risk of FN following chemotherapy. In particular, our systematic review identified 4 further RCTs of pegfilgrastim vs. no primary G-CSF, [22‐24] whereas at the time of a previous systematic review [18] only a single RCT [21] making this comparison was available. Although these 5 RCTs comparing pegfilgrastim with no primary G-CSF were heterogeneous in terms of clinical population and chemotherapy regimen, the pooled relative risk indicated a significant effect of pegfilgrastim in reducing FN incidence. Filgrastim and lenograstim also significantly reduced FN incidence.
This review also strengthens the evidence base regarding the comparative effectiveness of the three G-CSFs; in particular, comparison of the "once-per-cycle" G-CSF pegfilgrastim versus the "once-daily" G-CSF filgrastim. Meta-analysis of five RCTs indicated that FN incidence was significantly lower following primary prophylaxis with pegfilgrastim than with filgrastim. This is consistent with the fact that the reduction in FN risk for pegfilgrastim versus no primary G-CSF was greater than the reduction observed for filgrastim versus no primary G-CSF.
As discussed in previous reviews, [18, 19] there was heterogeneity among the studies in terms of the clinical population (age, cancer type), chemotherapy regimen, and cycle length and number. Correspondingly, heterogeneity was observed among the study results. Since individual studies differed on too many variables for formal sub-analyses to be meaningful, all studies were included in the analysis. There was no clear difference in G-CSF effectiveness between cancer types, nor in studies restricting to elderly populations. However, the variation in clinical population, and the corresponding high levels of heterogeneity, indicate that caution should be used when applying the results to individual clinical settings. Conversely, the range of populations and treatment regimens covered by the included studies is likely to reflect the variations which would be observed in clinical practice.
Conclusions
This systematic review and meta-analysis demonstrate that primary G-CSF prophylaxis with pegfilgrastim, filgrastim and lenograstim is effective in reducing the risk of FN in adults undergoing chemotherapy for solid tumours or lymphoma. In addition, although heterogeneity existed between studies, a meta-analysis suggests that pegfilgrastim reduces the risk of FN to a greater extent than filgrastim.
29 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
30 placebos/
31 placebos.ti,ab.
32 random.ti,ab.
33 research design/
34 randomised.ti,ab
35 randomized.ti,ab
36 or/20-35
37 19 and 36
("$" indicates truncations; "/" indicates medical subject headings)
Acknowledgements and funding
The research underlying this paper was funded by Amgen Ltd, and a research grant from Amgen (EUROPE) GmbH was provided to support the production of the manuscript. Amgen staff reviewed and made suggested edits to the manuscript, but final content, authorship and right to publication remained with the research team.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests
The research underlying this paper was funded by Amgen Ltd, and a research grant from Amgen (EUROPE) GmbH was provided to support the production of the manuscript. Amgen staff reviewed and made suggested edits to the manuscript, but final content, authorship and right to publication remained with the research team.
Authors' contributions
KC undertook the systematic review and drafted the manuscript. JM undertook the statistical analyses. SW contributed to study selection and interpretation. MS contributed to study selection and interpretation and to the statistical analyses. RA participated in the design and coordination of the study and contributed to the statistical analyses. All authors read and approved the final manuscript.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
